Basics TG Therapeutics, Inc. TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases. IPO Date: June 1, 2010 Sector: Healthcare Industry: Biotech Market Cap: $5.59B Activated in VL: True Average Daily Range Avg Daily Range: $0.45 | 3.20% Avg Daily Range (30 D): $0.80 | 2.11% Avg Daily Range (90 D): $0.96 | 2.70% Institutional Daily Volume Avg Daily Volume: 1.65M Avg Daily Volume (30 D): 2.3M Avg Daily Volume (90 D): 2.27M Trade Size Avg Trade Size (Sh.): 121 Avg Trade Size (Sh.) (30 D): 74 Avg Trade Size (Sh.) (90 D): 75 Institutional Trades Total Inst.Trades: 5,328 Avg Inst. Trade: $2.77M Avg Inst. Trade (30 D): $3.69M Avg Inst. Trade (90 D): $4.43M Avg Inst. Trade Volume: .15M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $4.79M Avg Closing Trade (30 D): $9.44M Avg Closing Trade (90 D): $10.79M Avg Closing Volume: 265.22K         News May 5, 2025 @ 11:00 AM TG Therapeutics Reports First Quarter 2025 Financi... Source: N/A Mar 9, 2025 @ 5:19 PM Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap G... Source: Lekha Gupta Nov 29, 2024 @ 1:00 PM TG Therapeutics to Participate in the Evercore Hea... Source: N/A Nov 21, 2024 @ 11:00 AM TG Therapeutics Ranked Number One Fastest-Growing ... Source: N/A Jun 27, 2024 @ 5:55 PM "Rule Breaker Investing" Market Cap Game Show: Bil... Source: newsfeedback@fool.com (Motley Fool Staff) Financials   TTM Q4 2024 FY 2024 Basic EPS $.03 $.16 $.16 Diluted EPS $.03 $.15 $.15 Revenue $ 120.86M $ 108.19M $ 329M Gross Profit $ 105.32M $ 92.79M $ 290.52M Net Income / Loss $ 5.06M $ 23.33M $ 23.38M Operating Income / Loss $ 8.62M $ 29.95M $ 41.93M Cost of Revenue $ 15.54M $ 15.4M $ 38.49M Net Cash Flow $ -47.75M $ -15.93M $ 86.97M PE Ratio 1,182.67     Splits Apr 30, 2012:   5:281 Jul 14, 2011:   1:50 Sep 25, 2003:   1:5